Key points are not available for this paper at this time.
伊伐卡特与肺功能在2周内的改善相关，并持续至48周。还观察到在肺部加重风险、患者报告的呼吸症状、体重和汗氯浓度方面的显著改善。（资助单位：Vertex Pharmaceuticals等；VX08-770-102 临床试验号，NCT00909532。）
Ramsey等人（星期三）研究了这个问题。
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: